Pictet Asset Management (UK)’s Myriad Genetics MYGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | $6.25M | Sell |
204,267
-16,987
| -8% | -$491K | 0.01% | 796 |
|
|
2021
Q1 | $6.74M | Sell |
221,254
-75,822
| -26% | -$2.15M | 0.01% | 769 |
|
|
2020
Q4 | $5.88M | Sell |
297,076
-20,100
| -6% | -$325K | 0.01% | 777 |
|
|
2020
Q3 | $4.14M | Sell |
317,176
-107,553
| -25% | -$1.36M | 0.01% | 766 |
|
|
2020
Q2 | $4.82M | Sell |
424,729
-62,689
| -13% | -$890K | 0.01% | 697 |
|
|
2020
Q1 | $6.97M | Buy |
487,418
+76,400
| +19% | +$1.61M | 0.01% | 557 |
|
|
2019
Q4 | $11.2M | Sell |
411,018
-66,866
| -14% | -$1.84M | 0.02% | 556 |
|
|
2019
Q3 | $13.7M | Buy |
477,884
+42,500
| +10% | +$1.24M | 0.03% | 468 |
|
|
2019
Q2 | $12.1M | Buy |
435,384
+113,288
| +35% | +$3.2M | 0.03% | 491 |
|
|
2019
Q1 | $10.7M | Buy |
322,096
+108,100
| +51% | +$3.29M | 0.02% | 525 |
|
|
2018
Q4 | $6.22K | Buy |
213,996
+58,200
| +37% | +$2.09M | 0.02% | 606 |
|
|
2018
Q3 | $7.17M | Sell |
155,796
-16,700
| -10% | -$743K | 0.02% | 640 |
|
|
2018
Q2 | $6.45M | Buy |
172,496
+119,900
| +228% | +$4.05M | 0.02% | 612 |
|
|
2018
Q1 | $1.55M | Sell |
52,596
-94,600
| -64% | -$3.2M | ﹤0.01% | 810 |
|
|
2017
Q4 | $5.05M | Buy |
147,196
+24,800
| +20% | +$837K | 0.01% | 656 |
|
|
2017
Q3 | $4.43M | Sell |
122,396
-5,000
| -4% | -$143K | 0.01% | 663 |
|
|
2017
Q2 | $2.59M | Buy |
127,396
+9,600
| +8% | +$204K | 0.01% | 748 |
|
|
2017
Q1 | $2.26M | Buy |
117,796
+2,200
| +2% | +$39K | 0.01% | 762 |
|
|
2016
Q4 | $1.93M | Buy |
115,596
+55,600
| +93% | +$1.01M | 0.01% | 752 |
|
|
2016
Q3 | $1.24M | Buy |
59,996
+3,000
| +5% | +$76.1K | ﹤0.01% | 771 |
|
|
2016
Q2 | $1.93M | Buy |
56,996
+30,796
| +118% | +$1.07M | 0.01% | 747 |
|
|
2016
Q1 | $917K | Hold |
26,200
| – | – | ﹤0.01% | 756 |
|
|
2015
Q4 | $1.13M | Sell |
26,200
-83,400
| -76% | -$3.52M | ﹤0.01% | 776 |
|
|
2015
Q3 | $4.11M | Sell |
109,600
-48,100
| -31% | -$1.71M | 0.02% | 596 |
|
|
2015
Q2 | $5.38M | Sell |
157,700
-62,000
| -28% | -$2.11M | 0.02% | 572 |
|
|
2015
Q1 | $7.26M | Buy |
219,700
+115,500
| +111% | +$4.13M | 0.03% | 495 |
|
|
2014
Q4 | $3.55M | Buy |
104,200
+1,400
| +1% | +$49.7K | 0.02% | 658 |
|
|
2014
Q3 | $3.96M | Sell |
102,800
-55,700
| -35% | -$2.08M | 0.02% | 591 |
|
|
2014
Q2 | $6.17M | Buy |
158,500
+35,800
| +29% | +$1.33M | 0.03% | 496 |
|
|
2014
Q1 | $4.2M | Buy |
122,700
+8,700
| +8% | +$270K | 0.02% | 571 |
|
|
2013
Q4 | $2.39M | Sell |
114,000
-48,300
| -30% | -$1.22M | 0.01% | 706 |
|
|
2013
Q3 | $3.81M | Sell |
162,300
-89,900
| -36% | -$2.55M | 0.02% | 593 |
|
|
2013
Q2 | $6.78M | Buy |
+252,200
| New | +$7.31M | 0.04% | 409 |
|
Other funds holding MYGN
PHS
CCM
GCM
Pictet Asset Management (UK)'s MYGN Position: Q2 2021 in Review
Pictet Asset Management (UK) reduced its Myriad Genetics (MYGN) stake by 7.7% in Q2 2021, selling an estimated $491K and leaving 204,267 shares worth $6.25M. The position accounts for 0.01% of the portfolio, ranked #796.
Pictet Asset Management (UK) first reported a position in MYGN in Q2 2013 and has held it in 33 quarters since. The position peaked at $13.7M in Q3 2019. 201 funds tracked by Wall St. Rank hold MYGN as of Q2 2021.
- Pictet Asset Management (UK) held 204,267 shares of Myriad Genetics worth $6.25M as of Q2 2021.
- Pictet Asset Management (UK) sold 16,987 Myriad Genetics shares in Q2 2021, an estimated $491K.
- Myriad Genetics made up 0.01% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #796 holding.
- Pictet Asset Management (UK) first reported a position in Myriad Genetics in Q2 2013 and has held it in 33 quarters since.
- Pictet Asset Management (UK)'s Myriad Genetics position peaked at $13.7M in Q3 2019.
- 201 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2021.
Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.